ATTY. DOCKET NO.: APPLICATION NO.: 87534-3100 09/644,456 APPLICANT: LIST OF REFERENCES CITED BY APPLICANT Vered HORNIK et al. (Use several sheets if necessary) FILING DATE: GROUP: August 24, 2000 1631 **U.S. PATENT DOCUMENTS** DOCUMENT NUMBER DATE avs SUBCLASS FILING DATE IF APPROPRIATE NAME 3,988,304 10/1976 Garsky 260 78A AB 4,011,182 03/1977 Sarantakis 260 8 AC 4,054,558 10/1977 Garsky 260 112.5S AD 4,187,217 02/1980 Chipens et al. 260 112.5R ΑE 4,235,886 11/1980 Freidinger et al. 424 177 AF 4,310,518 01/1982 Freidinger et al. 424 177 AG 5,364,851 11/1994 Joran 530 345 AH 5,371,070 12/1994 Koerber et al. 9 514 ΑI 5,770,687 01/1998 Hornik et al. 530 311 ΑJ 5,874,529 02/1999 Gilon et al. 530 317 ΑK 5,883,293 06/1999 Gilon et al. 562 455 MB ΑL 6,051,554 04/2000 Hornik et al. 514 11 FOREIGN PATENT DOCUMENTS CLASS SUBCLASS TRANSLATION DOCUMENT NUMBER DATE COUNTRY YES NO AM 2,304,352 10/1976 France AN 2,411,828 07/1979 France AO 0 031 303 07/1981 **EPO** AP WO 89/01781 03/1989 **PCT** MB AQ 0 334 244 A2 09/1989 **EPO** M Ms AR 0 336 779 A2 10/1989 **EPO** AS 0 370 453 B1 05/1990 **EPO** AT 0 395 417 10/1990 **EPO** w ΑU 0 336 779 A3 08/1991 **EPO** w ΑV WO 92/00091 01/1992 **PCT** AW 41 19 544 C1 10/1992 Germany AX WO 92/22566 12/1992 PCT

	4						rage	2 of 3				
1 200	从	AY	WO 93/01206	01/1993	PCT							
	3	ΑZ	0 564 739 A2	10/1993	ЕРО							
DE		ВА	WO 94/11393	05/1994	PCT							
		ВВ	WO 95/01800	01/1995	РСТ							
		вс	0 564 739 A3	04/1995	EPO							
1			OTHER RE	FERENCES (/	ncluding Author, Title, Date, Pertinent Pages	s, Etc.)						
\neg		BD	Bell et al., 1993, "Molecu	lar biology of s	omatostatin receptors," TINS, Vol. 16, No. 1,	34-38.						
		BE	Brazeau et al, 1973, "Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreative Pituitary Growth Hormone", SCIENCE, Vol. 179, pp. 77-79									
		BF			oliferation by the somatostatin analogue RC- ough different mechanisms," Proc. Natl. Acad							
		BG		Byk et al., 1992, "Building units for N-backbone cyclic peptides. 1. Synthesis of protected N-(ω-aminoalkylene)amino acids and their incorporation into dipeptide units", J. Org. Chem. 57:5687-5692								
		вн	Charpentier et al., 1989, "Synthesis and binding affinities of cyclic and related linear analogues of CCK ₈ selective for correceptors," J. Med. Chem., pp. 1184-1190.									
		ВІ	Giannis et al., 1993, "Peptidomimetics for receptor ligands - discovery, development, and medical perspectives," Angew. Chem. Int. Ed. Engl. 32: 1244-1267.									
		BJ	Gilon et al., 1991, "Backbone Cyclization: A New Method for Conferring Conformational Constraint on Peptides", Biopolymers 31:745-750									
		вк	Gilon et al., 1992, "SAR studies of cycloseptide: effects of cyclization and charge at position 6," Chem. Biol. Proc. Am. Pept. Symp 1th. pp. 476-477.									
		BL	Greiner et al., 1994, "Synthesis of New Backbone-Cyclized Bradykinin Analogs", Proc. Eur. Pept. Symp., 23rd, Meeting Dat 1994, 289-290									
		вм	Hruby et al., 1990, "Emerging approaches in the molecular design of receptor-selective peptide ligands: conformational, topographical and dynamic considerations," Biochem. J. 268: 249-262.									
		BN	Klein, et al., 1995, "Interleukin-6 in Human Multiple Myeloma," Blood, Vol. 85, No. 4, pp. 863-872.									
		во	Krstenansky et al., 1994, "Cyclic hexapeptide antagonists of the bradykinin B ₂ receptor: Receptor binding and solution backbone conformation", Letters in Peptide Science 1:229-234									
		ВР			in the regulation of anterior pituitary hormone Endocrine Reviews Vol. 9, No. 4, pp. 417-43		the use of	its anal	ogs			
		BQ	Lamberts et al., 1990, "Sor 1249.	mastatin-recepto	or imaging in the localization of endocrine tur	nors," New En	igland J. Me	ed. 323:	12			
		BR	Lymangrover et al., 1993, sciences 34:371-377.	"Varying the J	uration of A23187 administration alters its ef	fect on adrenal	steroidogei	nesis,"	Life			
		BS	Mosberg et al., 1983, "Bis Biochemistry 80:5871-58"		enkephalins possess highly improved specific	ity toward δ o	pioid recept	ors,"				
		вт	Plotsky et al., 1985, "Patte circulation of the rat," Sci		normone-releasing factor and somatostatin sec 63.	cretion into the	hypophysia	ıl-porta	l			
M	u	ВU	Raynor et al., 1993, "Clon	ed somatostatin	receptors: identification of subtype-selective	peptides and	demonstration	on of h	gh			

My		affinity binding of linear peptides," Mol. pharmacol. 43:838-844.						
1 4 2003	ву	Reisine et al., 1995, "Molecular biology of somatostatin receptors," Endocrine reviews 16, 427-442.						
4	ВW	tubi et al., 1995, "Multiple actions of somatostatin in neoplastic disease," TIPS 16: 110-115.						
OPA BY	вх	Rizo et al., 1992, "Constrained peptides: Models of bioactive peptides and protein substructures," Annu. Rev. Biochem. 61:387-418.						
	Rodriguez et al. 1990, "Synthesis of cyclic analogues of cholecystokinin highly selective for central receptors," Int. J. Peptide Protein Res. 35:441-451.							
	BZ	Rudinger, 1976, "Characteristics of the Amino Acids as components of a peptide hormone sequence," Peptide Hormones, Ed. J.A. Parsons, University Park Press, Baltimore, pp.1-7						
	CA	Schumann et al., 1996, Database Caplus, DN: 130:14228. Pept. 1996, Proc. Eur. Pept. Symp., 24th (1998). Meeting Date 1996, 797-798. Editors: Ramage, Robert; Epton, Roger. Publisher: Mayflower Scientific, Kingswinford, UK.						
	СВ	Steranka et al., 1988, "Bradykinin as a pain mediator: receptors are localized to sensory neurons, and antagonists have analgesic actions," Proc. Natl. Acad. Sci. USA 85:3245-3249.						
	СС	Verber et al., 1984, "A super active cyclic hexapeptide analog of somatostatin," Life sciences 34:1371-1378.						
	CD	Verber et al., 1985, "The design of metabolically-stable peptide analogs," TINS, pp. 392-396.						
My	CE	Zuckerman, 1993, "The chemical synthesis of peptidomimetic libraries," Current Opinion in Structure Biol., 3: 580-584.						
		EXAMINER DATE CONSIDERED O2/04/04						

in conformance and not considered. Include copy of this form with next communication to applicant.

T OF REFERENCES CITED BY APPLICANTS (Use several sheets if necessary)

ATT DOCKET NO	ADD, (24" (24 %)
2254-031-5 (*	09 644,456
APPLICANT	
HORNIK et al.	
FERIG DATE	\$#1.P
August 24 2000	11.51

U.S. PATENT DOCUMENTS								
*E1,44	A.		PARMUNT NUMBER	SATE	RECEIVED'	5-845:	F. N. CATE FARRE OFFETS	
M	ws	AA	5.639,455	6/1997	Shimamura et al. 0CT 0 2003 424	133.1		
		AB	5.470.942	11/1995	Alexander et al. TECH CENTER 1600/2900 Suto et al. 514	328		
<u></u>		AC	5.420.109	5/1995	Suto et al. 514	8		
N	m		5,210,075	5/1993	Scholz et al. 514	14		
				FORE	IGN PATENT DOCUMENTS			
			DOCUMENT NUMBER	CATE	coente cuass	SUBJUASS	******	
M	1/2	AE	WO 00/72864 A1	07/2000	PCT		165 NO	
		AF	WO 99/65508	12/1999	PCT			
		AG	WO 98/04583	2/1998	РСТ			
		АН	WO 97/48728	12/1997	PCT			
		Al	WO 97/13781	4/1997	PCT			
		AJ	WO 97/09344	3/1997	PCT			
		AF.	WO 95/33765	12/1995	PCT			
*	W)	AL	WO 95/13086	5/1995	PCT			
 ,-			OTHER RE	FERENCES (In	cluding Author, Title, Date, Pertinent Pages, Etc.			
M	1	AM	Hirano, T., 1998, "Inter	leukin 6 and	ts Receptor: Ten Years Later', Intern. Rev. Immuno	l., 16:249.		
		AN			Rheumatoid Arthritis by Blocking IL-6 Signal Transdu ody", Springer Semin. Immunopathol., 20: 247.	ıction with	a	
		ACı	Kozak et al., 1997, " Sickness Behavior in Mice Deficient in Interleukin-6 During Turpentine Abscess and Influenza Pneumonitis", American J. Physiology, 272: 2 R621.					
		AP	Simpson et al., 1997, "Interleukin-6: Structure-function Relationships", Protein Sci., 6: 929.					
		AQ	Xu et al., 1997, "Solution Structure of Recombinant Human Interleukin-6", J. Mol. Biol., 268: 468.					
		AR	Fourcin et al., 1996, "gp130 Transducing Receptor Cross-linking Is Sufficient to Induce Interleukin-6 Type Responses", J. Biol. Chem., 271: 11756.					
		AS	Murakamin-Mori et al., 1996, "The Soluble Form of the IL-6 Receptor (sIL-6Ra) Is a Potent Growth Factor for AIDS-associated Kaposi's sarcoma (KS) cells; the Soluble Form of gp130 Is Antagonistic for sIL-6Ra-Induced AIDS-KS Cell Growth", Int. Immunol., 8: 595.					
pr	Ogata, A., 1996, "Therapeutic Strategies of Inhibition of Interleukin-& Mediated Multiple Mycloma Cell Growth", Leuk. Res., 20: 303.							
FA FA	- 1 1							

Bioactivit,", The EMBO J., 15, 2725

Halimi et al., 1995, "Epitope Peptides from Interleukin-6 Receptor Which Inhibit the Growth of Human Marketing Control of the Experimental Con

en la main let a l'Orini l'entere de retion mattan. Multiple Myellin a l'about l'intollère l'

Sheet	1	of	2

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO	SHIAL NO	5
2254-031		4.0
APPLICANT		07
Vered HORNIK et al.	⇒ 3	
FRIONG DATE	GRUD	40
August 24, 2000		

			U.S.	PATENT DOCUMENTS			
*E KAMINER INITIAL		DOCUMENT NUMBER	DATE	NAMI	FLASS	SURF1 ASS	FILING DATE
M	AA_	3,988,304	10/1976	Garsky	260	78A	
1'	AB	4,011,182	03/1977	Sarantakis	260	8	
	AC	4,054,558	10/1977	Garsky	260	112.55	
	AD	4,187,217	02/1980	Chipens et al.	260	112.5R	
	ΑE	4,235,886	11/1980	Freidinger et al.	424	177	
	AF	4,310,518	01/1982	Freidinger et al.	424	177	
	AG	5,364,851	11/1994	Joran	530	345	
	АН	5,371,070	12/1994	Koerber et al.	514	9	
	ΑI	5,770,687	06/1998	Hornik et al.	530	311	
	AJ	5,874,529	02/1999	Gilon et a.	530	317	
	AK	5,883,293	06/1999	Gilon et al.	562	455	
MM	AL	6,051,554	04/2000	Hornik et al.	514	11	
			FOREIG	ON PATENT DOCUMENTS			

			FOREIC	ON PATENT DOCUMENTS				
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCI ASS	THANS	LATION
	├						YES	NO
My	AM	031 303	07/1981	European Patent Office				×
	AN	334 244	09/1989	European Patent Office				
	AO	336 779	10/1989	European Patent Office				
	АР	370 453	05/1990	European Patent Office				×
	AQ	395 417	10/1990	European Patent Office				
	AR	564 739	10/1993	European Patent Office				
L	AS	2 304 352	10/1976	France				×
	АТ	2 411 828	07/1979	France				×
<u> </u>	AU	41 19 544	10/1992	Germany				
	ΑV	WO 89/01781	03/1989	WIPO				
	AW	WO 92/00091	01/1992	WIPO				
	AX	WO 92/22566	12/1992	WIPO				×
	AY	WO 93/01206	01/1993	WIPO				
	AZ	WO 94/11393	05/1994	WIPO				
MI	ВА	WO 95/01800	01/1995	WIPO				

THE MESSAGE ST

Pitaltary Growth Hormone: Science 179.77-79.

Control of the Control

Buscall et al., 1995, "Inhibition of cell proliferation by the somatostatin analogue RC 160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different muchanisms." Proc. 5737.

Mom

02/04